Carcinoma, Non-Small-Cell Lung trials in Belgium: Trial Insights

Filters: Condition: Carcinoma, Non-Small-Cell Lung Country / region: Belgium Clear all

391 trials match Source: ClinicalTrials.gov registrations

Trials started per year
Category	Trials
2000	2
2001	2
2002	3
2003	4
2004	8
2005	5
2006	17
2007	13
2008	12
2009	8
2010	8
2011	10
2012	7
2013	16
2014	9
2015	23
2016	14
2017	22
2018	16
2019	23
2020	25
2021	22
2022	30
2023	22
2024	27
2025	26
2026	6

Trials by status
Category	Trials
Completed	162
Active, not recruiting	76
Terminated	66
Recruiting	62
Unknown status	19
Withdrawn	5
Available	1

Top lead sponsors
Category	Trials
Novartis Pharmaceuticals	33
AstraZeneca	29
Hoffmann-La Roche	28
Eli Lilly and Company	22
Bristol-Myers Squibb	19
European Organisation for Research and Treatment of Cancer - EORTC	15
Pfizer	14
EMD Serono Research & Development Institute, Inc.	10
GlaxoSmithKline	10
Bayer	9

Top conditions
Category	Trials
Carcinoma, Non-Small-Cell Lung	391
Lung Neoplasms	73
Neoplasms	33
Colorectal Neoplasms	31
Melanoma	31
Neoplasm Metastasis	27
Carcinoma, Renal Cell	22
Triple Negative Breast Neoplasms	22
Breast Neoplasms	19
Ovarian Neoplasms	18

Trials

Showing 76 to 100 of 391. Each trial links to its page on Pharma Observatory.

A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors NCT05462873Phase 1TerminatedNovartis PharmaceuticalsStarted 2023
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors NCT05856981Phase 1RecruitingSairopa B.V.Started 2023
Macrophage Imaging Using Ga-MMR-VHH2 in Lung Cancer Patients NCT05933239Phase 2RecruitingUniversitair Ziekenhuis BrusselStarted 2023
The Safety and Feasibility of Costal Bone Marrow Aspiration During Thoracic Surgery NCT05251805Not applicableTerminatedUniversitair Ziekenhuis BrusselStarted 2023
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer NCT05775289Phase 2CompletedHoffmann-La RocheStarted 2023
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) NCT05555732Phase 3Active, not recruitingDaiichi SankyoStarted 2023
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas NCT05751798Phase 1/2RecruitingOSE ImmunotherapeuticsStarted 2022
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours NCT05752552Phase 1RecruitingDeuterOncologyStarted 2022
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) NCT05668988Phase 3Active, not recruitingDizal PharmaceuticalsStarted 2022
A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) NCT05577715Phase 2TerminatedBristol-Myers SquibbStarted 2022
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors NCT05614102Phase 1Active, not recruitingBayerStarted 2022
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) NCT05170204Phase 3Active, not recruitingHoffmann-La RocheStarted 2022
PROspective Trial on EOsinophilia in Non-Small Cell Lung Cancer (NSCLC). NCT05602259Not applicableUnknown statusCentre Hospitalier Universitaire de LiegeStarted 2022
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors NCT05208762Phase 1RecruitingSeagen, a wholly owned subsidiary of PfizerStarted 2022
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation NCT05358249Phase 1/2Active, not recruitingNovartis PharmaceuticalsStarted 2022
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer NCT05620134Phase 1/2Active, not recruitingSalubris Biotherapeutics IncStarted 2022
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer NCT05565378Phase 2Active, not recruitingGlaxoSmithKlineStarted 2022
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer NCT05502237Phase 3Active, not recruitingGilead SciencesStarted 2022
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors NCT05537740Phase 1Active, not recruitingBayerStarted 2022
A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer NCT05005273Phase 2CompletedBristol-Myers SquibbStarted 2022
Tissue Eosinophils in Non-Small Cell Lung Cancer (the TEN Study) NCT05537701ObservationalActive, not recruitingCentre Hospitalier Universitaire de LiegeStarted 2022
Investigating the Feasibility of a Physical Activity (tele)coaching Intervention in Patients with Non-small Cell Lung Cancer: an Explorative Study NCT05569291Not applicableCompletedHasselt UniversityStarted 2022
A Study of Oncobax®-AK in Patients With Advanced Solid Tumors NCT05865730Phase 2Unknown statusEverImmuneStarted 2022
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy NCT05450692Phase 3Active, not recruitingAstraZenecaStarted 2022
Response and Toxicity Prediction by Microbiome Analysis After (Concurrent) Chemoradiotherapy NCT04711330ObservationalActive, not recruitingLeiden University Medical CenterStarted 2022

291 more trials match. See them on Pharma Observatory

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) NCT06236438Status changeRecruiting to Active, not recruitingOctober 22, 2026
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) NCT06236438Enrollment change840 to 167October 22, 2026
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT06417814Status changeRecruiting to Active, not recruitingOctober 17, 2026
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT06417814Enrollment change744 to 768October 17, 2026

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.

Visit Pharma Observatory